Schrödinger (SDGR) moved back into focus after multiple research firms updated their views on the business, linking higher fair value estimates to rising interest in AI driven drug discovery and recent commercial execution.
Recent trading has been volatile for Schrödinger, with the share price falling 2.9% on the day to US$29.99, yet still posting a 26.0% 7 day share price gain and a 98.1% 90 day share price return that point to building momentum.
Scan beyond Schrödinger and see how other AI focused healthcare stocks with fresh momentum stack up using our hand picked 36 healthcare AI stocks.
The latest surge in Schrödinger looks like a tug of war between enthusiasm for AI powered drug discovery and a share price already up sharply in 90 days. So how does that enthusiasm compare with where the valuation now sits?
Most Popular Narrative: 16% Overvalued
On Simply Wall St, the most followed narrative now pegs Schrödinger’s fair value at about $25.86, which sits below the latest close at $29.99 and indicates that the current enthusiasm may already reflect a significant amount of anticipated future execution.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $356.2 million, earnings will come to $25.4 million, and it would be trading on a PE ratio of 100.8x, assuming you use a discount rate of 8.2%.
See why 28 investors see Schrödinger as 16% overvalued.
Result: Fair Value of $25.86 (OVERVALUED)
Still, the story can unwind quickly if software growth remains concentrated in a few existing customers or if milestone and royalty income turns out to be more uneven than expected.
Find out about the key risks to this Schrödinger narrative.
Another View: Schrödinger’s Cash Flows Tell A Different Story
The first narrative around Schrödinger leans on analyst targets and implied P/E multiples and suggests the stock is about 16% overvalued at $29.99. Our DCF model points in the opposite direction, with SDGR trading roughly 28% below an estimated future cash flow value of $41.57.
That gap suggests investors are paying a premium on sales and near term optimism while still discounting the longer term cash generation implied by the SWS DCF model. It raises a simple question for you: Which set of assumptions feels more realistic for how this AI drug discovery story actually plays out?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Schrödinger for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 30 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around Schrödinger leave you torn, use that uncertainty as a prompt to move quickly, review the data carefully, and weigh both the concerns and the upside for yourself with the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Schrödinger?
Do not stop at Schrödinger. Broaden your watchlist with a few focused screens that surface different types of opportunities before they start attracting crowded attention.
- Target potential bargains by scanning companies that combine quality with attractive pricing using our 30 high quality undervalued stocks.
- Stress test your downside by zeroing in on companies with sturdier finances through the 30 resilient stocks with low risk scores.
- Get early access to lesser known prospects by searching for resilient businesses in the 18 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com